Zum Seiteninhalt springen
Back to overview


Amyloid Inhibitory Peptides for Alzheimer’s Disease and Diabetes

Life Sciences, Neurologie/ZNS

  • Macrocyclic peptides with drug-like properties
  • Highly potent inhibitors of Aβ amyloid self-assembly
  • Promising in vivo data from Alzheimer’s mouse model

Ihr Kontakt

Dr. M. Charlotte Hemmer

+49 (0) 89 5480177 - 29


Despite the established association between the pathogenesis of Alzheimer’s disease (AD) and the presence of amyloid plaques of β‐amyloid peptide (Aβ) in the brain, all anti‐Aβ therapeutic strategies, mostly representing antibody-based approaches aiming at blocking amyloid self-assembly have so far failed. However, the development of anti-amyloid compounds is an important target of AD-related research. For this reason, there is an urgent need to develop novel classes of amyloid inhibitors.


Here, we present synthetic medium sized macrocyclic peptides, termed macrocyclic inhibitory peptides (MCIPs), as a new class of highly potent inhibitors of amyloid self-assembly and related cytotoxic effects¹. The drug-like properties of our lead MCIP 2Einclude their small size (<20 amino acids), high solubility, potent amyloid inhibitor function (nanomolar IC50) and Aβ40(42) binding affinity, target selectivity, good proteolytic stability in human plasma (in vitro) und BBB permeability (determined using in vitro models), and make them suitable drug candidates. For instance, one of the weak points of the antibodies is their extremely low BBB permeability.

Kommerzielle Möglichkeiten

Our lead macrocyclic peptide 2E was confirmed as a potent inhibitor of amyloidogenesis in several in vitro assays1 and a mouse model of Alzheimer’s disease (unpublished data):

  • MW < 2000 Da
  • Cost-effective production by routine solid phase peptide synthesis
  • High solubility
  • High Aβ40(42) binding affinity and amyloid inhibitor potency (nanomolar IC50)
  • Good proteolytic stability in human plasma (in vitro)
  • Effective crossing of human blood brain barrier (BBB) (in cell model)
  • Promising data from behavioral tests with no observed in vivo toxicity in mouse model


Proof of concept of lead compound in 5xFAD mouse model of Alzheimer’s disease.


  • 1

    doi: 10.1002/anie.201802979

Haben wir Ihr Interesse geweckt?

Finden Sie den richtigen Ansprechpartner auf unserer Team-Seite oder benutzen Sie für Ihre Anfrage einfach das Kontakt-Formular.


Diese Webseite verwendet Cookies. Cookies verbessern die Nutzung und helfen uns diese Website an Ihre Bedürfnisse anzupassen.